Resistance in gram-negative bacteria: enterobacteriaceae.

By David L. Paterson. American Journal of Medicine, 2006

1,005 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Role of Epidemic Resistance Plasmids and International High-Risk Clones in the Spread of Multidrug-Resistant Enterobacteriaceae (2015, background): “The Enterobacteriaceae, especially Escherichia coli and Klebsiella pneumoniae, are common causes of nosocomial and community infections among humans (1).”
Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It (2020, background): “Resistance is mainly related to the production of ESBLs, but other mechanisms of resistance are also emerging, leading to multidrug-resistance (MDR) [10].”
Characterization of a New Metallo-β-Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India (2009, background): “-Lactams have been the mainstay of treatment for serious infections, and the most active of these are the carbapenems, which are advocated for use for the treatment of infections caused by extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, particularly Escherichia coli and Klebsiella ”
Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli (2007, background): “pneumoniae; however, carbapenem resistance is emerging in certain geographic areas (27, 43, 52, 54, 79).”